Dataset Information
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.
Ontology highlight
ABSTRACT:
SUBMITTER: Brandao M
PROVIDER: S-EPMC6555612 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature